Skip to main content
global hero background

Frequently Asked Questions

About PLUVICTO

Who can take PLUVICTO

Efficacy & Safety

Dosing & Administration

Patient Access

PSMA-PET

References: 1. Armstrong AJ, Morris MJ, Abida W, et al. Trial design and objectives for patients with prostate cancer: Recommendations from the Prostate Cancer Working Group 4. J Clin Oncol. 2026;44(13):1249-1265. doi:10.1200/JCO-25-02834 2. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 3. Holik HA, Ibrahim FM, Elaine AA, et al. The chemical scaffold of theranostic radiopharmaceuticals: Radionuclide, bifunctional chelator, and pharmacokinetics modifying linker. Molecules. 2022;27(10):3062. doi:10.3390/molecules27103062 4. Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022;6(1):103-117. doi:10.7150/ntno.64141 5. Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020;48(5):1339-1350. doi:10.1007/s00259-020-05057-6 6. Nonnekens J, van Kranenburg M, Beerens CEMT, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6(11):1821-1832. doi:10.7150/thno.15311 7. Fendler WP, Stuparu AD, Evans-Axelsson S, et al. Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med. 2017;58(11):1786-1792. doi:10.2967/jnumed.117.193359 8. Data on file. PLUVICTO PSMAddition final analysis. Novartis Pharmaceuticals Corp; June 2026. 9. Data on file. PLUVICTO PSMAddition trial. Novartis Pharmaceuticals Corp; June 2026. 10. Morris MJ, Castellano D, Herrmann K, et al; PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2 11. Centers for Disease Control and Prevention. Guidelines for ALARA—as low as reasonably achievable. https://www.cdc.gov/radiation-health/safety/alara.html. Accessed December 4, 2024. 12. Data on file. PLUVICTO NPS Metrics. Novartis Pharmaceuticals Corp; March 2026. 13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed January 23, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. 14. Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466-1486. doi:10.1007/s00259-022-06089-w  
15. Ferdinandus J, Fendler WP, Farolfi A, et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology biochemical recurrence risk groups: an international multicenter study. J Nucl Med. 2022;63(1):76-80. doi:10.2967/jnumed.121.262821 16. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698 17. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573 18. ClinicalTrials.gov. Gallium Ga 68-labeled PSMA-11 PET/ CT in detecting recurrent prostate cancer in patients after initial therapy. https://clinicaltrials.gov/study/NCT02940262. Accessed June 24, 2026. 19. Unterrainer LM, Hope TA, Fendler WP, et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET—an international multicenter retrospective study. J Nucl Med. 2025;66(1):54-60. doi:10.2967/jnumed.124.268441